Obinutuzumab + Lenalidomide Delivers 93% 2-Year PFS in First-Line High-Tumor-Burden FL

Obinutuzumab, a type II anti-CD20 antibody with enhanced ADCC, paired with the IMiD lenalidomide (G-Len) was tested in a single-center phase 2 trial (NCT02871219) in 90 untreated grade 1-3a, stage II–IV follicular-lymphoma patients meeting GELF high-tumor-burden criteria. Six induction cycles were followed by 24 maintenance cycles. After 70.7 mo median follow-up, 2-year PFS reached 93% (95% CI 88–99) and median PFS was not reached; 30-mo complete-response rate hit 90%. Any-grade diarrhea (61%), rash (53%), and fatigue (52%) dominated; grade ≥3 neutropenia 19%, rash 11%, pneumonia 7%. By comparison, obinutuzumab-chemo in the GALLIUM study posted ~88% 2-year PFS with grade ≥3 neutropenia 46%, while the chemo-free R² regimen (lenalidomide + rituximab) achieved ~81% at 2 years—placing G-Len at the top of the frontline PFS leaderboard so far.